Inactive Ingredient Search for Approved Drug Products
Search Names Beginning with A
Inactive Ingredient | Route | Dosage Form | CAS Number | UNII | Maximum Potency per unit dose | Maximum Daily Exposure (MDE) | Record Updated |
---|---|---|---|---|---|---|---|
.ALPHA.-TERPINEOL | TOPICAL | LOTION | 98555 | 21334LVV8W | 11%w/w | ||
.ALPHA.-TOCOPHEROL | BUCCAL | FILM, SOLUBLE | 1406184 | H4N855PNZ1 | 0.07mg | ||
.ALPHA.-TOCOPHEROL | INTRAVENOUS | INJECTION, POWDER, FOR SUSPENSION | 1406184 | H4N855PNZ1 | 0.64mg | ||
.ALPHA.-TOCOPHEROL | ORAL | CAPSULE | 1406184 | H4N855PNZ1 | 16mg | ||
.ALPHA.-TOCOPHEROL | ORAL | SOLUTION | 1406184 | H4N855PNZ1 | 1.05mg/1ml | ||
.ALPHA.-TOCOPHEROL | ORAL | TABLET | 1406184 | H4N855PNZ1 | 1mg | ||
.ALPHA.-TOCOPHEROL | ORAL | TABLET, CHEWABLE | 1406184 | H4N855PNZ1 | 0.1mg | ||
.ALPHA.-TOCOPHEROL | ORAL | TABLET, EXTENDED RELEASE | 1406184 | H4N855PNZ1 | 4mg | ||
.ALPHA.-TOCOPHEROL | ORAL | TABLET, FILM COATED | 1406184 | H4N855PNZ1 | 246mg | ||
.ALPHA.-TOCOPHEROL | TOPICAL | OINTMENT | 1406184 | H4N855PNZ1 | NA | ||
.ALPHA.-TOCOPHEROL | TOPICAL | SYSTEM | 1406184 | H4N855PNZ1 | 0.1mg | ||
.ALPHA.-TOCOPHEROL ACETATE | BUCCAL | FILM | 7695912 | 9E8X80D2L0 | 0.09mg | ||
.ALPHA.-TOCOPHEROL ACETATE | ORAL | CAPSULE | 7695912 | 9E8X80D2L0 | 2mg | ||
.ALPHA.-TOCOPHEROL ACETATE | ORAL | TABLET | 7695912 | 9E8X80D2L0 | 0.5mg | ||
.ALPHA.-TOCOPHEROL ACETATE, DL- | TOPICAL | AEROSOL, FOAM | 52225204 | WR1WPI7EW8 | NA | ||
.ALPHA.-TOCOPHEROL ACETATE, DL- | TOPICAL | OINTMENT | 52225204 | WR1WPI7EW8 | NA | ||
.ALPHA.-TOCOPHEROL, DL- | INTRAVENOUS | INJECTION, EMULSION | 10191410 | 7QWA1RIO01 | 178mg | ||
.ALPHA.-TOCOPHEROL, DL- | INTRAVENOUS | SOLUTION, CONCENTRATE | 10191410 | 7QWA1RIO01 | 0.08%w/v | ||
.ALPHA.-TOCOPHEROL, DL- | ORAL | CAPSULE | 10191410 | 7QWA1RIO01 | 7mg | ||
.ALPHA.-TOCOPHEROL, DL- | ORAL | POWDER, FOR SUSPENSION | 10191410 | 7QWA1RIO01 | NA | ||
.ALPHA.-TOCOPHEROL, DL- | ORAL | SUSPENSION | 10191410 | 7QWA1RIO01 | 0.01mg/1ml | ||
.ALPHA.-TOCOPHEROL, DL- | ORAL | TABLET | 10191410 | 7QWA1RIO01 | 0.12mg | ||
.ALPHA.-TOCOPHEROL, DL- | ORAL | TABLET, CHEWABLE | 10191410 | 7QWA1RIO01 | 0.02mg | ||
.ALPHA.-TOCOPHEROL, DL- | TOPICAL | AEROSOL, FOAM | 10191410 | 7QWA1RIO01 | NA | ||
.ALPHA.-TOCOPHEROL, DL- | TOPICAL | OINTMENT | 10191410 | 7QWA1RIO01 | NA | ||
.ALPHA.-TOCOPHEROL, DL- | TRANSDERMAL | SYSTEM | 10191410 | 7QWA1RIO01 | 0.14mg | ||
ACACIA | BUCCAL | GUM, CHEWING | 9000015 | 5C5403N26O | 280mg | ||
ACACIA | BUCCAL | TABLET | 9000015 | 5C5403N26O | 9.1mg | ||
ACACIA | INTRAMUSCULAR | SUSPENSION | 9000015 | 5C5403N26O | 1mg | ||
ACACIA | ORAL | CAPSULE | 9000015 | 5C5403N26O | 64mg | ||
ACACIA | ORAL | CAPSULE, EXTENDED RELEASE | 9000015 | 5C5403N26O | 51mg | ||
ACACIA | ORAL | LOZENGE | 9000015 | 5C5403N26O | 108mg | ||
ACACIA | ORAL | POWDER | 9000015 | 5C5403N26O | 800mg | ||
ACACIA | ORAL | POWDER, FOR SOLUTION | 9000015 | 5C5403N26O | NA | ||
ACACIA | ORAL | POWDER, FOR SUSPENSION | 9000015 | 5C5403N26O | 7386mg | ||
ACACIA | ORAL | SUSPENSION | 9000015 | 5C5403N26O | 2mg | ||
ACACIA | ORAL | SYRUP | 9000015 | 5C5403N26O | NA | ||
ACACIA | ORAL | TABLET | 9000015 | 5C5403N26O | 70mg | ||
ACACIA | ORAL | TABLET, CHEWABLE | 9000015 | 5C5403N26O | 121mg | ||
ACACIA | ORAL | TABLET, COATED | 9000015 | 5C5403N26O | 156mg | ||
ACACIA | ORAL | TABLET, DELAYED RELEASE | 9000015 | 5C5403N26O | 30mg | ||
ACACIA | ORAL | TABLET, EXTENDED RELEASE | 9000015 | 5C5403N26O | 34.4mg | ||
ACACIA | ORAL | TABLET, FILM COATED | 9000015 | 5C5403N26O | 0.14mg | ||
ACACIA | ORAL | TABLET, ORALLY DISINTEGRATING | 9000015 | 5C5403N26O | 7mg | ||
ACACIA | SUBLINGUAL | TABLET | 9000015 | 5C5403N26O | 9.1mg | ||
ACACIA SYRUP | ORAL | CAPSULE, EXTENDED RELEASE | 8047378 | NA | 69.64mg | ||
ACACIA SYRUP | ORAL | TABLET, DELAYED RELEASE | 8047378 | NA | NA | ||
ACESULFAME | ORAL | SOLUTION | 33665906 | MA3UYZ6K1H | 120mg | ||
ACESULFAME POTASSIUM | BUCCAL | GUM, CHEWING | 55589623 | 23OV73Q5G9 | 147mg | ||
ACESULFAME POTASSIUM | DENTAL | SOLUTION | 55589623 | 23OV73Q5G9 | 0.12%w/w | ||
ACESULFAME POTASSIUM | ORAL | FILM, SOLUBLE | 55589623 | 23OV73Q5G9 | 1.6mg | ||
ACESULFAME POTASSIUM | ORAL | LOZENGE | 55589623 | 23OV73Q5G9 | 120mg | ||
ACESULFAME POTASSIUM | ORAL | POWDER, FOR SOLUTION | 55589623 | 23OV73Q5G9 | 117mg | ||
ACESULFAME POTASSIUM | ORAL | POWDER, FOR SUSPENSION | 55589623 | 23OV73Q5G9 | 45mg/5ml | ||
ACESULFAME POTASSIUM | ORAL | SOLUTION | 55589623 | 23OV73Q5G9 | 400mg | ||
ACESULFAME POTASSIUM | ORAL | SUSPENSION | 55589623 | 23OV73Q5G9 | 160mg | ||
ACESULFAME POTASSIUM | ORAL | TABLET | 55589623 | 23OV73Q5G9 | 111mg | ||
ACESULFAME POTASSIUM | ORAL | TABLET, CHEWABLE | 55589623 | 23OV73Q5G9 | 8mg | ||
ACESULFAME POTASSIUM | ORAL | TABLET, EFFERVESCENT | 55589623 | 23OV73Q5G9 | 4mg | ||
ACESULFAME POTASSIUM | ORAL | TABLET, FILM COATED | 55589623 | 23OV73Q5G9 | 1.75mg | ||
ACESULFAME POTASSIUM | ORAL | TABLET, FOR SUSPENSION | 55589623 | 23OV73Q5G9 | 72mg | ||
ACESULFAME POTASSIUM | ORAL | TABLET, ORALLY DISINTEGRATING | 55589623 | 23OV73Q5G9 | 24mg | ||
ACESULFAME POTASSIUM | ORAL | TROCHE | 55589623 | 23OV73Q5G9 | 26mg | ||
ACESULFAME POTASSIUM | SUBLINGUAL | FILM | 55589623 | 23OV73Q5G9 | 5mg | ||
ACESULFAME POTASSIUM | SUBLINGUAL | TABLET | 55589623 | 23OV73Q5G9 | 13mg | ||
ACETIC ACID | AURICULAR (OTIC) | SUSPENSION | 64197 | Q40Q9N063P | 0.26%w/v | ||
ACETIC ACID | AURICULAR (OTIC) | SUSPENSION/ DROPS | 64197 | Q40Q9N063P | 0.04%w/v | ||
ACETIC ACID | ENDOTRACHEAL | SUSPENSION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | INFILTRATION | INJECTION | 64197 | Q40Q9N063P | NA | ||
ACETIC ACID | INTRA-ARTICULAR | INJECTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | INTRALESIONAL | INJECTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | INTRAMUSCULAR | INJECTION | 64197 | Q40Q9N063P | 22mg | Y | |
ACETIC ACID | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | INTRAMUSCULAR | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | INTRASYNOVIAL | INJECTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | INTRAVENOUS | INJECTION | 64197 | Q40Q9N063P | 827mg | ||
ACETIC ACID | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 64197 | Q40Q9N063P | 3mg | ||
ACETIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 64197 | Q40Q9N063P | 15mg | ||
ACETIC ACID | INTRAVENOUS | LIQUID | 64197 | Q40Q9N063P | 0.2%w/v | ||
ACETIC ACID | INTRAVENOUS | SOLUTION | 64197 | Q40Q9N063P | 14mg | ||
ACETIC ACID | IRRIGATION | SOLUTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | NASAL | SPRAY, METERED | 64197 | Q40Q9N063P | 1.2mg/1ml | ||
ACETIC ACID | OPHTHALMIC | SOLUTION | 64197 | Q40Q9N063P | 0.04%w/v | ||
ACETIC ACID | OPHTHALMIC | SOLUTION/ DROPS | 64197 | Q40Q9N063P | 0.09%w/v | ||
ACETIC ACID | ORAL | CAPSULE | 64197 | Q40Q9N063P | NA | ||
ACETIC ACID | ORAL | CAPSULE, COATED | 64197 | Q40Q9N063P | 1mg | ||
ACETIC ACID | ORAL | ELIXIR | 64197 | Q40Q9N063P | 1.07mg/5ml | ||
ACETIC ACID | ORAL | LIQUID | 64197 | Q40Q9N063P | 0.13mg/5ml | ||
ACETIC ACID | ORAL | SOLUTION | 64197 | Q40Q9N063P | 10mg | ||
ACETIC ACID | ORAL | SUSPENSION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | ORAL | SYRUP | 64197 | Q40Q9N063P | 10mg | ||
ACETIC ACID | ORAL | TABLET | 64197 | Q40Q9N063P | NA | ||
ACETIC ACID | PARENTERAL | INJECTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | SOFT TISSUE | INJECTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | SUBCUTANEOUS | INJECTION | 64197 | Q40Q9N063P | 22mg | Y | |
ACETIC ACID | SUBCUTANEOUS | INJECTION, POWDER, FOR SOLUTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 64197 | Q40Q9N063P | 32mg | Y | |
ACETIC ACID | SUBCUTANEOUS | INJECTION, SOLUTION | 64197 | Q40Q9N063P | 4mg | ||
ACETIC ACID | SUBCUTANEOUS | LIQUID | 64197 | Q40Q9N063P | 0.2%w/v | ||
ACETIC ACID | SUBCUTANEOUS | SOLUTION | 64197 | Q40Q9N063P | 0.06%w/v | ||
ACETIC ACID | SUBMUCOSAL | INJECTION, SOLUTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | TOPICAL | CREAM | 64197 | Q40Q9N063P | NA | ||
ACETIC ACID | TOPICAL | SOLUTION | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | TOPICAL | SPONGE | 64197 | Q40Q9N063P | ADJ PH | ||
ACETIC ACID | VAGINAL | AEROSOL, FOAM | 64197 | Q40Q9N063P | 0.03%w/w | ||
ACETIC ACID | VAGINAL | CREAM | 64197 | Q40Q9N063P | 0.35%w/w | ||
ACETIC ACID | VAGINAL | JELLY | 64197 | Q40Q9N063P | 1.1%w/w | ||
ACETIC ANHYDRIDE | INTRAVENOUS | INJECTION | 108247 | 2E48G1QI9Q | NA | ||
ACETIC ANHYDRIDE | ORAL | TABLET, EXTENDED RELEASE | 108247 | 2E48G1QI9Q | 0.11mg | ||
ACETONITRILE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 75058 | Z072SB282N | 8424mg | Y | |
ACETYLTRIBUTYL CITRATE | ORAL | CAPSULE | 77907 | 0ZBX0N59RZ | 7mg | ||
ACETYLTRIBUTYL CITRATE | ORAL | CAPSULE, COATED | 77907 | 0ZBX0N59RZ | 11mg | ||
ACETYLTRIBUTYL CITRATE | ORAL | CAPSULE, DELAYED RELEASE | 77907 | 0ZBX0N59RZ | 122mg | Y | |
ACETYLTRIBUTYL CITRATE | ORAL | CAPSULE, EXTENDED RELEASE | 77907 | 0ZBX0N59RZ | 23mg | ||
ACETYLTRIBUTYL CITRATE | ORAL | TABLET | 77907 | 0ZBX0N59RZ | 150mg | ||
ACETYLTRIBUTYL CITRATE | ORAL | TABLET, DELAYED RELEASE | 77907 | 0ZBX0N59RZ | 69mg | ||
ACETYLTRIBUTYL CITRATE | ORAL | TABLET, EXTENDED RELEASE | 77907 | 0ZBX0N59RZ | 309mg | ||
ACETYLTRIBUTYL CITRATE | TOPICAL | SOLUTION | 77907 | 0ZBX0N59RZ | 5.4%w/w | ||
ACRYLATES COPOLYMER | ORAL | TABLET | NA | 10mg | |||
ACRYLATES COPOLYMER | ORAL | TABLET, CHEWABLE | NA | 5.05mg | |||
ACRYLATES COPOLYMER | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | NA | 25.18mg | |||
ACRYLATES COPOLYMER | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | 382.22mg | |||
ACRYLATES COPOLYMER | TRANSDERMAL | SYSTEM | NA | 677.68mg | |||
ACRYL-EZE 93018509 WHITE | ORAL | TABLET | NA | 153mg | |||
ACRYL-EZE 93018509 WHITE | ORAL | TABLET, EXTENDED RELEASE | NA | 48mg | |||
ACRYL-EZE 93084720 PINK | ORAL | TABLET, DELAYED RELEASE | NA | 234mg | |||
ACRYLIC ACID-2-ETHYLHEXYL ACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 87-2070) | TRANSDERMAL | FILM, EXTENDED RELEASE | T9DNB7TEC3 | NA | |||
ACRYLIC ACID-2-ETHYLHEXYL ACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 87-2070) | TRANSDERMAL | SYSTEM | T9DNB7TEC3 | NA | |||
ACRYLIC ACID-ISOOCTYL ACRYLATE COPOLYMER | TRANSDERMAL | FILM, EXTENDED RELEASE | 9017689 | NA | 169mg | ||
ACRYLIC ADHESIVE 788 | TRANSDERMAL | SYSTEM | NA | 45mg | |||
ADCOTE 72A103 | TRANSDERMAL | SYSTEM | NA | 16mg | |||
ADHESIVE TAPE | TOPICAL | DISC | NA | NA | |||
ADHESIVE TAPE | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | NA | |||
ADIPIC ACID | INTRAMUSCULAR | INJECTION | 124049 | 76A0JE0FKJ | 1%w/v | ||
ADIPIC ACID | VAGINAL | INSERT | 124049 | 76A0JE0FKJ | 171mg | ||
ADVANTIA PRIME 190100BA01 WHITE | ORAL | TABLET, COATED | NA | 3mg | |||
ADVANTIA PRIME 190100BA01 WHITE | ORAL | TABLET, FILM COATED | NA | 6mg | |||
AGAR | ORAL | TABLET | 9002180 | 89T13OHQ2B | 0.2mg | ||
ALBUMIN HUMAN | INTRAVENOUS | INJECTION, POWDER, FOR SUSPENSION | 9048468 | ZIF514RVZR | 900mg | ||
ALBUMINS | ORAL | TABLET, FILM COATED | NA | 4.5mg | |||
ALCLOXA | TOPICAL | CREAM | 1317255 | 18B8O9DQA2 | 0.25%w/w | ||
ALCOHOL | BUCCAL | CONCENTRATE | 64175 | 3K9958V90M | 679mg/1ml | ||
ALCOHOL | BUCCAL | MOUTHWASH | 64175 | 3K9958V90M | 200mg/1ml | ||
ALCOHOL | DENTAL | GEL | 64175 | 3K9958V90M | 1.8%w/w | ||
ALCOHOL | DENTAL | PASTE | 64175 | 3K9958V90M | 1.8%w/w | ||
ALCOHOL | DENTAL | SOLUTION | 64175 | 3K9958V90M | 12.8%w/w | ||
ALCOHOL | INTRAMUSCULAR | INJECTION | 64175 | 3K9958V90M | 1491mg | ||
ALCOHOL | INTRAMUSCULAR | INJECTION, SOLUTION | 64175 | 3K9958V90M | 1000mg | ||
ALCOHOL | INTRAMUSCULAR | LIQUID | 64175 | 3K9958V90M | 400mg | ||
ALCOHOL | INTRAVASCULAR | INJECTION | 64175 | 3K9958V90M | 100%v/v | ||
ALCOHOL | INTRAVENOUS | INJECTION | 64175 | 3K9958V90M | 92%w/v | ||
ALCOHOL | INTRAVENOUS | INJECTION, EMULSION | 64175 | 3K9958V90M | 520mg | ||
ALCOHOL | INTRAVENOUS | INJECTION, SOLUTION | 64175 | 3K9958V90M | 4650mg | ||
ALCOHOL | INTRAVENOUS | LIQUID | 64175 | 3K9958V90M | 400mg | ||
ALCOHOL | INTRAVENOUS | SOLUTION | 64175 | 3K9958V90M | 5%v/v | ||
ALCOHOL | INTRAVENOUS | SOLUTION, CONCENTRATE | 64175 | 3K9958V90M | 4000mg | ||
ALCOHOL | INTRAVESICAL | SOLUTION | 64175 | 3K9958V90M | 7892mg | ||
ALCOHOL | NASAL | AEROSOL | 64175 | 3K9958V90M | 20mg | ||
ALCOHOL | NASAL | AEROSOL, METERED | 64175 | 3K9958V90M | 70mg | ||
ALCOHOL | NASAL | DROPS | 64175 | 3K9958V90M | 10mg/1ml | ||
ALCOHOL | NASAL | SOLUTION | 64175 | 3K9958V90M | 10mg/1ml | ||
ALCOHOL | NASAL | SPRAY | 64175 | 3K9958V90M | 198.8mg/1ml | ||
ALCOHOL | OPHTHALMIC | SOLUTION | 64175 | 3K9958V90M | 0.5%w/v | ||
ALCOHOL | ORAL | CAPSULE | 64175 | 3K9958V90M | 882mg | Y | |
ALCOHOL | ORAL | CONCENTRATE | 64175 | 3K9958V90M | 198mg | ||
ALCOHOL | ORAL | DROPS | 64175 | 3K9958V90M | 210mg/1ml | ||
ALCOHOL | ORAL | ELIXIR | 64175 | 3K9958V90M | 3744mg | ||
ALCOHOL | ORAL | LIQUID | 64175 | 3K9958V90M | 3563mg | ||
ALCOHOL | ORAL | SOLUTION | 64175 | 3K9958V90M | 6624mg | ||
ALCOHOL | ORAL | SOLUTION, CONCENTRATE | 64175 | 3K9958V90M | 150.68mg/1ml | ||
ALCOHOL | ORAL | SUSPENSION | 64175 | 3K9958V90M | 681mg | ||
ALCOHOL | ORAL | SYRUP | 64175 | 3K9958V90M | 21000mg | ||
ALCOHOL | RECTAL | GEL | 64175 | 3K9958V90M | 898mg | ||
ALCOHOL | RECTAL | SUSPENSION | 64175 | 3K9958V90M | 0.35%v/v | ||
ALCOHOL | RESPIRATORY (INHALATION) | AEROSOL, METERED | 64175 | 3K9958V90M | 52mg | ||
ALCOHOL | RESPIRATORY (INHALATION) | AEROSOL, SPRAY | 64175 | 3K9958V90M | 35.75%w/w | ||
ALCOHOL | RESPIRATORY (INHALATION) | LIQUID | 64175 | 3K9958V90M | 5%w/w | ||
ALCOHOL | RESPIRATORY (INHALATION) | SOLUTION | 64175 | 3K9958V90M | 0.08%w/v | ||
ALCOHOL | SUBCUTANEOUS | INJECTION | 64175 | 3K9958V90M | 149mg | ||
ALCOHOL | SUBCUTANEOUS | INJECTION, SOLUTION | 64175 | 3K9958V90M | 6.1%v/v | ||
ALCOHOL | SUBLINGUAL | SPRAY | 64175 | 3K9958V90M | 397mg | ||
ALCOHOL | SUBLINGUAL | SPRAY, METERED | 64175 | 3K9958V90M | 29mg | ||
ALCOHOL | TOPICAL | AEROSOL | 64175 | 3K9958V90M | 561mg | ||
ALCOHOL | TOPICAL | AEROSOL, FOAM | 64175 | 3K9958V90M | 4504mg | ||
ALCOHOL | TOPICAL | AEROSOL, SPRAY | 64175 | 3K9958V90M | 561mg | ||
ALCOHOL | TOPICAL | GEL | 64175 | 3K9958V90M | 9971mg | ||
ALCOHOL | TOPICAL | GEL, METERED | 64175 | 3K9958V90M | 525mg | ||
ALCOHOL | TOPICAL | LOTION | 64175 | 3K9958V90M | 25%w/w | ||
ALCOHOL | TOPICAL | POWDER, FOR SOLUTION | 64175 | 3K9958V90M | 40%w/w | ||
ALCOHOL | TOPICAL | SHAMPOO | 64175 | 3K9958V90M | 714mg | ||
ALCOHOL | TOPICAL | SOLUTION | 64175 | 3K9958V90M | 2440mg | ||
ALCOHOL | TOPICAL | SPRAY | 64175 | 3K9958V90M | 3633mg | ||
ALCOHOL | TOPICAL | SWAB | 64175 | 3K9958V90M | 2250mg | ||
ALCOHOL | TRANSDERMAL | GEL | 64175 | 3K9958V90M | 7258mg | ||
ALCOHOL | TRANSDERMAL | GEL, METERED | 64175 | 3K9958V90M | 525mg | Y | |
ALCOHOL | TRANSDERMAL | SOLUTION | 64175 | 3K9958V90M | 49.37%w/v | ||
ALCOHOL | TRANSDERMAL | SPRAY | 64175 | 3K9958V90M | 90%w/v | ||
ALCOHOL | VAGINAL | JELLY | 64175 | 3K9958V90M | NA | ||
ALFADEX | INTRACAVITARY | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10016203 | Z1LH97KTRM | 1.29mg | ||
ALGELDRATE | ORAL | TABLET | 1330445 | 03J11K103C | 85mg | ||
ALGELDRATE | ORAL | TABLET, FILM COATED | 1330445 | 03J11K103C | 183.75mg | ||
ALGELDRATE | TOPICAL | CREAM | 1330445 | 03J11K103C | 5%w/w | ||
ALGINIC ACID | OPHTHALMIC | INSERT, EXTENDED RELEASE | 9005327 | 8C3Z4148WZ | 1mg | ||
ALGINIC ACID | ORAL | CAPSULE | 9005327 | 8C3Z4148WZ | 80mg | ||
ALGINIC ACID | ORAL | CAPSULE, EXTENDED RELEASE | 9005327 | 8C3Z4148WZ | 10mg | ||
ALGINIC ACID | ORAL | TABLET | 9005327 | 8C3Z4148WZ | 128mg | ||
ALGINIC ACID | ORAL | TABLET, CHEWABLE | 9005327 | 8C3Z4148WZ | 400mg | ||
ALGINIC ACID | ORAL | TABLET, COATED | 9005327 | 8C3Z4148WZ | 60mg | ||
ALGINIC ACID | ORAL | TABLET, EXTENDED RELEASE | 9005327 | 8C3Z4148WZ | 22.25mg | ||
ALGINIC ACID | ORAL | TABLET, FILM COATED | 9005327 | 8C3Z4148WZ | 52.8mg | ||
ALLANTOIN | TOPICAL | GEL | 97596 | 344S277G0Z | 8mg | ||
ALMOND OIL | TOPICAL | CREAM | 8007690 | 66YXD4DKO9 | 2%w/w | ||
ALUMINUM ACETATE | TOPICAL | CREAM | 139128 | 80EHD8I43D | 0.23%w/w | ||
ALUMINUM ACETATE | TOPICAL | SHAMPOO | 139128 | 80EHD8I43D | 0.1%w/w | ||
ALUMINUM HYDROXIDE | ORAL | CAPSULE | 21645512 | 5QB0T2IUN0 | NA | ||
ALUMINUM HYDROXIDE | ORAL | TABLET | 21645512 | 5QB0T2IUN0 | 50mg | ||
ALUMINUM HYDROXIDE | TOPICAL | CREAM | 21645512 | 5QB0T2IUN0 | 5%w/w | ||
ALUMINUM HYDROXIDE | TOPICAL | OINTMENT | 21645512 | 5QB0T2IUN0 | NA | ||
ALUMINUM MONOSTEARATE | TOPICAL | CREAM | 7047849 | P9BC99461E | 0.01%w/w | ||
ALUMINUM OXIDE | ORAL | CAPSULE, EXTENDED RELEASE | 1344281 | LMI26O6933 | NA | ||
ALUMINUM OXIDE | ORAL | TABLET | 1344281 | LMI26O6933 | NA | ||
ALUMINUM OXIDE | TOPICAL | SPONGE | 1344281 | LMI26O6933 | NA | ||
ALUMINUM POLYESTER | TRANSDERMAL | FILM | NA | 10mg | |||
ALUMINUM POLYESTER | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | 81mg | |||
ALUMINUM SILICATE | ORAL | TABLET | 12141467 | T1FAD4SS2M | 19.25mg | ||
ALUMINUM SILICATE | ORAL | TABLET, COATED | 12141467 | T1FAD4SS2M | 50mg | ||
ALUMINUM SILICATE | ORAL | TABLET, EXTENDED RELEASE | 12141467 | T1FAD4SS2M | 94mg | ||
ALUMINUM SILICATE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 12141467 | T1FAD4SS2M | 47mg | ||
ALUMINUM SILICATE | TOPICAL | SYSTEM | 12141467 | T1FAD4SS2M | 19mg | ||
ALUMINUM SILICATE PENTAHYDRATE | ORAL | TABLET, COATED | IQ2A4DQ696 | NA | |||
ALUMINUM STARCH OCTENYLSUCCINATE | TOPICAL | CREAM | 9087610 | I9PJ0O6294 | 10%w/w | ||
ALUMINUM STEARATE | ORAL | CAPSULE, EXTENDED RELEASE | 637127 | U6XF9NP8HM | 1mg | ||
ALUMINUM STEARATE | ORAL | TABLET | 637127 | U6XF9NP8HM | 6mg | ||
ALUMINUM STEARATE | ORAL | TABLET, EXTENDED RELEASE | 637127 | U6XF9NP8HM | 105mg | ||
ALUMINUM STEARATE | TOPICAL | CREAM | 637127 | U6XF9NP8HM | 0.01%w/w | ||
ALUMINUM STEARATE | TOPICAL | OINTMENT | 637127 | U6XF9NP8HM | 0.01%w/w | ||
ALUMINUM SULFATE | TOPICAL | CREAM | 17927650 | 34S289N54E | 14mg | ||
ALUMINUM SULFATE ANHYDROUS | AURICULAR (OTIC) | SOLUTION | 10043013 | I7T908772F | 0.79%w/w | ||
ALUMINUM SULFATE ANHYDROUS | TOPICAL | CREAM | 10043013 | I7T908772F | 0.13%w/w | ||
ALUMINUM SULFATE ANHYDROUS | TOPICAL | LOTION | 10043013 | I7T908772F | NA | ||
ALZAMER-50 | ORAL | TABLET, EXTENDED RELEASE | NA | 32mg | |||
AMARANTH | BUCCAL | TROCHE | 915673 | 37RBV3X49K | 0.05mg | ||
AMARANTH | ORAL | CAPSULE | 915673 | 37RBV3X49K | 1.08mg | ||
AMARANTH | ORAL | CAPSULE, EXTENDED RELEASE | 915673 | 37RBV3X49K | 0.18mg | ||
AMARANTH | ORAL | ELIXIR | 915673 | 37RBV3X49K | 1.88mg | ||
AMARANTH | ORAL | LIQUID | 915673 | 37RBV3X49K | NA | ||
AMARANTH | ORAL | SOLUTION | 915673 | 37RBV3X49K | 0.11mg/1ml | ||
AMARANTH | ORAL | SUSPENSION | 915673 | 37RBV3X49K | 0.1mg/1ml | ||
AMARANTH | ORAL | SYRUP | 915673 | 37RBV3X49K | 0.03mg/1ml | ||
AMARANTH | ORAL | TABLET | 915673 | 37RBV3X49K | 0.48mg | ||
AMARANTH | ORAL | TABLET, COATED | 915673 | 37RBV3X49K | 0.02mg | ||
AMARANTH | ORAL | TABLET, FILM COATED | 915673 | 37RBV3X49K | 0.01mg | ||
AMARANTH | TOPICAL | SHAMPOO | 915673 | 37RBV3X49K | 0.57%w/w | ||
AMBERLITE | ORAL | CAPSULE | 9079258 | NA | 4.86mg | ||
AMBERLITE | ORAL | TABLET | 9079258 | NA | 110mg | ||
AMBERLITE | ORAL | TABLET, COATED | 9079258 | NA | NA | ||
AMBERLITE | ORAL | TABLET, FILM COATED | 9079258 | NA | 25mg | ||
AMBERLITE XE-88 | ORAL | TABLET | 9002340 | NA | 10mg | ||
AMBERLITE XE-88 | ORAL | TABLET, COATED | 9002340 | NA | 11mg | ||
AMBERLITE XE-88 | ORAL | TABLET, FILM COATED | 9002340 | NA | 30mg | ||
AMBERLITE XE-88 | ORAL | WAFER | 9002340 | NA | 8mg | ||
AMERCHOL-CAB | TOPICAL | OINTMENT | 8029047 | NA | 10%w/w | ||
AMINOBENZOATE SODIUM | ORAL | CAPSULE | 555066 | 75UI7QUZ5J | NA | ||
AMINOBENZOATE SODIUM | ORAL | TABLET | 555066 | 75UI7QUZ5J | NA | ||
AMINOMETHYLPROPANOL | TOPICAL | CREAM | 124685 | LU49E6626Q | 1%w/w | ||
AMINOMETHYLPROPANOL | TOPICAL | LOTION | 124685 | LU49E6626Q | 0.3%w/w | ||
AMMONIA SOLUTION | INTRAVENOUS | INJECTION | 7664417 | 5138Q19F1X | 0.22%w/v | ||
AMMONIA SOLUTION | OPHTHALMIC | SOLUTION | 7664417 | 5138Q19F1X | ADJ PH | ||
AMMONIA SOLUTION | ORAL | CAPSULE | 7664417 | 5138Q19F1X | 0.01mg | ||
AMMONIA SOLUTION | ORAL | CAPSULE, DELAYED RELEASE | 7664417 | 5138Q19F1X | 2mg | ||
AMMONIA SOLUTION | ORAL | CAPSULE, EXTENDED RELEASE | 7664417 | 5138Q19F1X | NA | ||
AMMONIA SOLUTION | ORAL | SUSPENSION | 7664417 | 5138Q19F1X | NA | ||
AMMONIA SOLUTION | ORAL | TABLET | 7664417 | 5138Q19F1X | NA | ||
AMMONIA SOLUTION | ORAL | TABLET, DELAYED RELEASE | 7664417 | 5138Q19F1X | NA | ||
AMMONIA SOLUTION | ORAL | TABLET, EXTENDED RELEASE | 7664417 | 5138Q19F1X | 6mg | ||
AMMONIA SOLUTION | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 7664417 | 5138Q19F1X | NA | ||
AMMONIA SOLUTION | SUBCUTANEOUS | INJECTION | 7664417 | 5138Q19F1X | ADJ PH | ||
AMMONIA SOLUTION | SUBLINGUAL | FILM | 7664417 | 5138Q19F1X | NA | ||
AMMONIA SOLUTION | TOPICAL | CREAM | 7664417 | 5138Q19F1X | 5.72%w/w | ||
AMMONIA SOLUTION | TOPICAL | GEL | 7664417 | 5138Q19F1X | 1.2%w/w | ||
AMMONIA SOLUTION | TOPICAL | LOTION | 7664417 | 5138Q19F1X | ADJ PH | ||
AMMONIO METHACRYLATE COPOLYMER | ORAL | CAPSULE, EXTENDED RELEASE | NA | 6mg | |||
AMMONIO METHACRYLATE COPOLYMER | ORAL | TABLET | NA | NA | |||
AMMONIO METHACRYLATE COPOLYMER TYPE A | ORAL | CAPSULE, EXTENDED RELEASE | 33434241 | 8GQS4E66YY | 64mg | ||
AMMONIO METHACRYLATE COPOLYMER TYPE A | ORAL | POWDER, FOR SUSPENSION | 33434241 | 8GQS4E66YY | 161mg/5ml | ||
AMMONIO METHACRYLATE COPOLYMER TYPE A | ORAL | TABLET, EXTENDED RELEASE | 33434241 | 8GQS4E66YY | 361mg | ||
AMMONIO METHACRYLATE COPOLYMER TYPE A | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 33434241 | 8GQS4E66YY | 25mg | ||
AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | CAPSULE | 33434241 | 161H3B14U2 | 38mg | ||
AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | CAPSULE, EXTENDED RELEASE | 33434241 | 161H3B14U2 | 1972mg | ||
AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | TABLET | 33434241 | 161H3B14U2 | 600mg | ||
AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | TABLET, CHEWABLE | 33434241 | 161H3B14U2 | 100mg | ||
AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | TABLET, EXTENDED RELEASE | 33434241 | 161H3B14U2 | 440mg | ||
AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | TABLET, FILM COATED | 33434241 | 161H3B14U2 | 32mg | ||
AMMONIUM ACETATE | INTRAMUSCULAR | INJECTION | 631618 | RRE756S6Q2 | 160mg | ||
AMMONIUM ACETATE | INTRAVENOUS | INJECTION | 631618 | RRE756S6Q2 | 160mg | ||
AMMONIUM CALCIUM ALGINATE | ORAL | TABLET | NA | 10.72mg | |||
AMMONIUM CHLORIDE | ORAL | CAPSULE | 12125029 | 01Q9PC255D | 8mg | ||
AMMONIUM CHLORIDE | ORAL | SYRUP | 12125029 | 01Q9PC255D | 131.68mg/5ml | ||
AMMONIUM CHLORIDE | ORAL | TABLET | 12125029 | 01Q9PC255D | 8mg | ||
AMMONIUM CHLORIDE | ORAL | TABLET, EXTENDED RELEASE | 12125029 | 01Q9PC255D | 21mg | ||
AMMONIUM CHLORIDE | ORAL | TABLET, FILM COATED | 12125029 | 01Q9PC255D | 8mg | ||
AMMONIUM LAURYL SULFATE | TOPICAL | AEROSOL | 2235543 | Q7AO2R1M0B | NA | ||
AMMONIUM LAURYL SULFATE | TOPICAL | EMULSION | 2235543 | Q7AO2R1M0B | 39.75%w/w | ||
AMMONIUM LAURYL SULFATE | TOPICAL | SHAMPOO, SUSPENSION | 2235543 | Q7AO2R1M0B | 30%w/w | ||
AMMONIUM PHOSPHATE, DIBASIC | ORAL | TABLET | 7783280 | 10LGE70FSU | 0.4mg | ||
AMMONIUM PHOSPHATE, DIBASIC | ORAL | TABLET, EXTENDED RELEASE | 7783280 | 10LGE70FSU | 0.4mg | ||
AMMONIUM PHOSPHATE, DIBASIC | SUBLINGUAL | TABLET | 7783280 | 10LGE70FSU | 0.2mg | ||
AMMONIUM SULFATE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 7783202 | SU46BAM238 | 81mg | ||
AMMONIUM SULFATE | INTRAVENOUS | INJECTION, SUSPENSION, LIPOSOMAL | 7783202 | SU46BAM238 | 0.2%w/v | ||
AMPHOTERIC-9 | TOPICAL | CREAM | 627910321 | NA | 0.66%w/w | ||
ANETHOLE | DENTAL | PASTE, DENTIFRICE | 4180238 | Q3JEK5DO4K | 9.4%w/w | ||
ANETHOLE | DENTAL | SOLUTION | 4180238 | Q3JEK5DO4K | NA | ||
ANETHOLE | ORAL | ELIXIR | 4180238 | Q3JEK5DO4K | 0.03mg | ||
ANETHOLE | ORAL | SYRUP | 4180238 | Q3JEK5DO4K | 2.3mg/5ml | ||
ANHYDROUS CITRIC ACID | BUCCAL | FILM | 77929 | XF417D3PSL | 9mg | ||
ANHYDROUS CITRIC ACID | BUCCAL | FILM, SOLUBLE | 77929 | XF417D3PSL | 2mg | ||
ANHYDROUS CITRIC ACID | INTRACARDIAC | INJECTION | 77929 | XF417D3PSL | 25mg | ||
ANHYDROUS CITRIC ACID | INTRAMUSCULAR | INJECTION | 77929 | XF417D3PSL | 25mg | ||
ANHYDROUS CITRIC ACID | INTRAMUSCULAR | INJECTION, SOLUTION | 77929 | XF417D3PSL | 25mg | ||
ANHYDROUS CITRIC ACID | INTRAVENOUS | CONCENTRATE | 77929 | XF417D3PSL | ADJ PH | ||
ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION | 77929 | XF417D3PSL | 510mg | ||
ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 77929 | XF417D3PSL | 35mg | Y | |
ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 77929 | XF417D3PSL | 414mg | ||
ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 77929 | XF417D3PSL | 540mg | ||
ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, SOLUTION, CONCENTRATE | 77929 | XF417D3PSL | 81mg | ||
ANHYDROUS CITRIC ACID | INTRAVENOUS | LIQUID | 77929 | XF417D3PSL | 18mg | ||
ANHYDROUS CITRIC ACID | INTRAVENOUS | SOLUTION, CONCENTRATE | 77929 | XF417D3PSL | 60mg | ||
ANHYDROUS CITRIC ACID | NASAL | SPRAY | 77929 | XF417D3PSL | 5mg | ||
ANHYDROUS CITRIC ACID | NASAL | SPRAY, METERED | 77929 | XF417D3PSL | 1.2mg/1ml | ||
ANHYDROUS CITRIC ACID | OPHTHALMIC | SOLUTION | 77929 | XF417D3PSL | 0.09%w/v | ||
ANHYDROUS CITRIC ACID | OPHTHALMIC | SUSPENSION/ DROPS | 77929 | XF417D3PSL | 0.05%w/v | ||
ANHYDROUS CITRIC ACID | ORAL | CAPSULE | 77929 | XF417D3PSL | 131mg | ||
ANHYDROUS CITRIC ACID | ORAL | CAPSULE, LIQUID FILLED | 77929 | XF417D3PSL | 360mg | ||
ANHYDROUS CITRIC ACID | ORAL | CONCENTRATE | 77929 | XF417D3PSL | 84mg | ||
ANHYDROUS CITRIC ACID | ORAL | ELIXIR | 77929 | XF417D3PSL | 90mg | ||
ANHYDROUS CITRIC ACID | ORAL | FILM, SOLUBLE | 77929 | XF417D3PSL | 7mg | ||
ANHYDROUS CITRIC ACID | ORAL | GRANULE, FOR SUSPENSION | 77929 | XF417D3PSL | 29mg | ||
ANHYDROUS CITRIC ACID | ORAL | LIQUID | 77929 | XF417D3PSL | 12mg | ||
ANHYDROUS CITRIC ACID | ORAL | LOZENGE | 77929 | XF417D3PSL | 9.8mg | ||
ANHYDROUS CITRIC ACID | ORAL | PASTE | 77929 | XF417D3PSL | 26mg | ||
ANHYDROUS CITRIC ACID | ORAL | POWDER, FOR SOLUTION | 77929 | XF417D3PSL | 123mg | ||
ANHYDROUS CITRIC ACID | ORAL | POWDER, FOR SUSPENSION | 77929 | XF417D3PSL | 570mg | ||
ANHYDROUS CITRIC ACID | ORAL | SOLUTION | 77929 | XF417D3PSL | 2262mg | ||
ANHYDROUS CITRIC ACID | ORAL | SUSPENSION | 77929 | XF417D3PSL | 400mg | ||
ANHYDROUS CITRIC ACID | ORAL | SUSPENSION, EXTENDED RELEASE | 77929 | XF417D3PSL | 62mg | ||
ANHYDROUS CITRIC ACID | ORAL | SUSPENSION/ DROPS | 77929 | XF417D3PSL | 15mg | ||
ANHYDROUS CITRIC ACID | ORAL | SYRUP | 77929 | XF417D3PSL | 268mg | ||
ANHYDROUS CITRIC ACID | ORAL | TABLET | 77929 | XF417D3PSL | 40mg | ||
ANHYDROUS CITRIC ACID | ORAL | TABLET, CHEWABLE | 77929 | XF417D3PSL | 4mg | ||
ANHYDROUS CITRIC ACID | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 77929 | XF417D3PSL | 12mg | ||
ANHYDROUS CITRIC ACID | ORAL | TABLET, EFFERVESCENT | 77929 | XF417D3PSL | 840mg | ||
ANHYDROUS CITRIC ACID | ORAL | TABLET, EXTENDED RELEASE | 77929 | XF417D3PSL | 312mg | ||
ANHYDROUS CITRIC ACID | ORAL | TABLET, ORALLY DISINTEGRATING | 77929 | XF417D3PSL | 46mg | ||
ANHYDROUS CITRIC ACID | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 77929 | XF417D3PSL | 48mg | ||
ANHYDROUS CITRIC ACID | RECTAL | SUSPENSION | 77929 | XF417D3PSL | 904mg | ||
ANHYDROUS CITRIC ACID | RESPIRATORY (INHALATION) | SOLUTION | 77929 | XF417D3PSL | 1mg | ||
ANHYDROUS CITRIC ACID | RESPIRATORY (INHALATION) | SUSPENSION | 77929 | XF417D3PSL | 1mg | ||
ANHYDROUS CITRIC ACID | SUBCUTANEOUS | INJECTION | 77929 | XF417D3PSL | 25mg | ||
ANHYDROUS CITRIC ACID | SUBCUTANEOUS | INJECTION, SOLUTION | 77929 | XF417D3PSL | 25mg | ||
ANHYDROUS CITRIC ACID | SUBLINGUAL | FILM | 77929 | XF417D3PSL | 11mg | ||
ANHYDROUS CITRIC ACID | SUBLINGUAL | TABLET | 77929 | XF417D3PSL | 36mg | ||
ANHYDROUS CITRIC ACID | SUBLINGUAL | TABLET, ORALLY DISINTEGRATING | 77929 | XF417D3PSL | ADJ PH | ||
ANHYDROUS CITRIC ACID | TOPICAL | AEROSOL | 77929 | XF417D3PSL | 0.08%w/w | ||
ANHYDROUS CITRIC ACID | TOPICAL | AEROSOL, FOAM | 77929 | XF417D3PSL | 6mg | ||
ANHYDROUS CITRIC ACID | TOPICAL | CLOTH | 77929 | XF417D3PSL | 4.2mg | ||
ANHYDROUS CITRIC ACID | TOPICAL | CREAM | 77929 | XF417D3PSL | 1mg | ||
ANHYDROUS CITRIC ACID | TOPICAL | GEL | 77929 | XF417D3PSL | 3mg | ||
ANHYDROUS CITRIC ACID | TOPICAL | LOTION | 77929 | XF417D3PSL | 211mg | ||
ANHYDROUS CITRIC ACID | TOPICAL | OIL | 77929 | XF417D3PSL | 2mg | ||
ANHYDROUS CITRIC ACID | TOPICAL | SHAMPOO | 77929 | XF417D3PSL | 0.07%w/w | ||
ANHYDROUS CITRIC ACID | TOPICAL | SOLUTION | 77929 | XF417D3PSL | 4.35%w/v | ||
ANHYDROUS CITRIC ACID | TOPICAL | SPRAY | 77929 | XF417D3PSL | 0.01%w/w | ||
ANHYDROUS CITRIC ACID | TRANSMUCOSAL | LOZENGE | 77929 | XF417D3PSL | 11mg | ||
ANHYDROUS DEXTROSE | INTRAMUSCULAR | INJECTION | 50997 | 5SL0G7R0OK | 300mg | ||
ANHYDROUS DEXTROSE | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | 50997 | 5SL0G7R0OK | 3.9%w/v | ||
ANHYDROUS DEXTROSE | INTRASPINAL | INJECTION | 50997 | 5SL0G7R0OK | 8.25%w/v | ||
ANHYDROUS DEXTROSE | INTRAVENOUS | INJECTION | 50997 | 5SL0G7R0OK | 36000mg | ||
ANHYDROUS DEXTROSE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 50997 | 5SL0G7R0OK | 3.9%w/v | ||
ANHYDROUS DEXTROSE | INTRAVENOUS | INJECTION, SOLUTION | 50997 | 5SL0G7R0OK | 5%w/v | ||
ANHYDROUS DEXTROSE | NASAL | SPRAY, METERED | 50997 | 5SL0G7R0OK | 25mg | ||
ANHYDROUS DEXTROSE | ORAL | GRANULE, FOR SUSPENSION | 50997 | 5SL0G7R0OK | 16878mg | ||
ANHYDROUS DEXTROSE | ORAL | POWDER | 50997 | 5SL0G7R0OK | 0.5mg | ||
ANHYDROUS DEXTROSE | ORAL | TABLET, CHEWABLE | 50997 | 5SL0G7R0OK | 1592mg | Y | |
ANHYDROUS DEXTROSE | ORAL | TABLET, EXTENDED RELEASE | 50997 | 5SL0G7R0OK | 30mg | ||
ANHYDROUS DEXTROSE | SUBCUTANEOUS | INJECTION | 50997 | 5SL0G7R0OK | 7.5%w/v | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | BUCCAL | TABLET | 7757939 | L11K75P92J | 60mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | DENTAL | PASTE, DENTIFRICE | 7757939 | L11K75P92J | 48.36%w/w | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | CAPSULE | 7757939 | L11K75P92J | 401mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | CAPSULE, EXTENDED RELEASE | 7757939 | L11K75P92J | 301.7mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | PASTILLE | 7757939 | L11K75P92J | NA | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | SYRUP | 7757939 | L11K75P92J | NA | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET | 7757939 | L11K75P92J | 2240mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET, CHEWABLE | 7757939 | L11K75P92J | 50mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET, COATED | 7757939 | L11K75P92J | 333.3mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET, DELAYED RELEASE | 7757939 | L11K75P92J | 2834mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET, EXTENDED RELEASE | 7757939 | L11K75P92J | 360mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET, FILM COATED | 7757939 | L11K75P92J | 1111mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET, FOR SUSPENSION | 7757939 | L11K75P92J | 406mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | SUBLINGUAL | POWDER | 7757939 | L11K75P92J | 30mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | SUBLINGUAL | TABLET | 7757939 | L11K75P92J | 28mg | ||
ANHYDROUS DIBASIC CALCIUM PHOSPHATE | TOPICAL | CREAM | 7757939 | L11K75P92J | 36%w/w | ||
ANHYDROUS LACTOSE | BUCCAL | TABLET | 63423 | 3SY5LH9PMK | 48mg | ||
ANHYDROUS LACTOSE | INTRAMUSCULAR | INJECTION | 63423 | 3SY5LH9PMK | 25mg | ||
ANHYDROUS LACTOSE | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | 63423 | 3SY5LH9PMK | 25mg | ||
ANHYDROUS LACTOSE | INTRAVENOUS | INJECTION | 63423 | 3SY5LH9PMK | 375mg | ||
ANHYDROUS LACTOSE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 63423 | 3SY5LH9PMK | 25mg | ||
ANHYDROUS LACTOSE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 63423 | 3SY5LH9PMK | 375mg | ||
ANHYDROUS LACTOSE | ORAL | CAPSULE | 63423 | 3SY5LH9PMK | 2490mg | ||
ANHYDROUS LACTOSE | ORAL | CAPSULE, DELAYED RELEASE | 63423 | 3SY5LH9PMK | 360mg | ||
ANHYDROUS LACTOSE | ORAL | CAPSULE, EXTENDED RELEASE | 63423 | 3SY5LH9PMK | 869mg | ||
ANHYDROUS LACTOSE | ORAL | GRANULE, FOR SUSPENSION | 63423 | 3SY5LH9PMK | 3025mg | ||
ANHYDROUS LACTOSE | ORAL | POWDER | 63423 | 3SY5LH9PMK | 5mg | ||
ANHYDROUS LACTOSE | ORAL | POWDER, FOR SUSPENSION | 63423 | 3SY5LH9PMK | 469mg | ||
ANHYDROUS LACTOSE | ORAL | SUSPENSION | 63423 | 3SY5LH9PMK | 15.69mg/5ml | ||
ANHYDROUS LACTOSE | ORAL | TABLET | 63423 | 3SY5LH9PMK | 1800mg | ||
ANHYDROUS LACTOSE | ORAL | TABLET, CHEWABLE | 63423 | 3SY5LH9PMK | 2850mg | ||
ANHYDROUS LACTOSE | ORAL | TABLET, COATED | 63423 | 3SY5LH9PMK | 504mg | ||
ANHYDROUS LACTOSE | ORAL | TABLET, DELAYED RELEASE | 63423 | 3SY5LH9PMK | 1083mg | ||
ANHYDROUS LACTOSE | ORAL | TABLET, EXTENDED RELEASE | 63423 | 3SY5LH9PMK | 529mg | ||
ANHYDROUS LACTOSE | ORAL | TABLET, FILM COATED | 63423 | 3SY5LH9PMK | 2906mg | ||
ANHYDROUS LACTOSE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 63423 | 3SY5LH9PMK | 316mg | ||
ANHYDROUS LACTOSE | ORAL | TABLET, FOR SUSPENSION | 63423 | 3SY5LH9PMK | 15mg | ||
ANHYDROUS LACTOSE | ORAL | TABLET, ORALLY DISINTEGRATING | 63423 | 3SY5LH9PMK | 410mg | ||
ANHYDROUS LACTOSE | SUBLINGUAL | TABLET | 63423 | 3SY5LH9PMK | 128mg | ||
ANHYDROUS TRISODIUM CITRATE | INTRA-ARTICULAR | INJECTION | 68042 | RS7A450LGA | 1%w/v | ||
ANHYDROUS TRISODIUM CITRATE | INTRABURSAL | INJECTION | 68042 | RS7A450LGA | 1%w/v | ||
ANHYDROUS TRISODIUM CITRATE | INTRALESIONAL | INJECTION | 68042 | RS7A450LGA | 0.96%w/v | ||
ANHYDROUS TRISODIUM CITRATE | INTRAMUSCULAR | INJECTION | 68042 | RS7A450LGA | 792mg | ||
ANHYDROUS TRISODIUM CITRATE | INTRAVENOUS | CONCENTRATE | 68042 | RS7A450LGA | 24mg | ||
ANHYDROUS TRISODIUM CITRATE | INTRAVENOUS | INJECTION | 68042 | RS7A450LGA | 792mg | ||
ANHYDROUS TRISODIUM CITRATE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 68042 | RS7A450LGA | 69.9mg | ||
ANHYDROUS TRISODIUM CITRATE | NASAL | SPRAY | 68042 | RS7A450LGA | 8mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | GRANULE, EFFERVESCENT | 68042 | RS7A450LGA | 935mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | GRANULE, FOR SUSPENSION | 68042 | RS7A450LGA | 4000mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | POWDER, FOR SOLUTION | 68042 | RS7A450LGA | 48mg/5ml | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | POWDER, FOR SUSPENSION | 68042 | RS7A450LGA | 232mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | SOLUTION | 68042 | RS7A450LGA | 240mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | SUSPENSION | 68042 | RS7A450LGA | 21mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | SUSPENSION, EXTENDED RELEASE | 68042 | RS7A450LGA | 47mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | TABLET | 68042 | RS7A450LGA | 720mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | TABLET, CHEWABLE | 68042 | RS7A450LGA | 72.5mg | ||
ANHYDROUS TRISODIUM CITRATE | ORAL | TABLET, DELAYED RELEASE | 68042 | RS7A450LGA | 15mg | ||
ANHYDROUS TRISODIUM CITRATE | RESPIRATORY (INHALATION) | SUSPENSION | 68042 | RS7A450LGA | 2mg | ||
ANHYDROUS TRISODIUM CITRATE | SOFT TISSUE | INJECTION | 68042 | RS7A450LGA | 0.96%w/v | ||
ANHYDROUS TRISODIUM CITRATE | SUBCUTANEOUS | INJECTION | 68042 | RS7A450LGA | 0.94%w/v | ||
ANHYDROUS TRISODIUM CITRATE | SUBLINGUAL | FILM | 68042 | RS7A450LGA | 4mg | ||
ANHYDROUS TRISODIUM CITRATE | SUBLINGUAL | TABLET | 68042 | RS7A450LGA | 36mg | ||
ANHYDROUS TRISODIUM CITRATE | TOPICAL | CREAM | 68042 | RS7A450LGA | 4mg | ||
ANHYDROUS TRISODIUM CITRATE | TOPICAL | LOTION | 68042 | RS7A450LGA | 0.08%w/w | ||
ANIDRISORB 85/70 | ORAL | CAPSULE | NA | 170mg | |||
ANIDRISORB 85/70 | ORAL | CAPSULE, LIQUID FILLED | NA | 187mg | |||
ANISE | ORAL | ELIXIR | 21C2F5E8RE | 0.15mg/5ml | |||
ANISE | ORAL | SOLUTION | 21C2F5E8RE | 72mg | |||
ANISE OIL | DENTAL | PASTE, DENTIFRICE | 8007703 | 6Y89129C8H | NA | ||
ANISE OIL | DENTAL | POWDER, DENTIFRICE | 8007703 | 6Y89129C8H | NA | ||
ANISE OIL | ORAL | DROPS | 8007703 | 6Y89129C8H | 0.4mg/1ml | ||
ANISE OIL | ORAL | ELIXIR | 8007703 | 6Y89129C8H | 0.15ml/5ml | ||
ANISE OIL | ORAL | PASTILLE | 8007703 | 6Y89129C8H | 16mg | ||
ANISE OIL | ORAL | SOLUTION | 8007703 | 6Y89129C8H | 1.4mg | ||
ANISE OIL | ORAL | SUSPENSION | 8007703 | 6Y89129C8H | 1ml/5ml | ||
ANOXID SBN | TOPICAL | CREAM | NA | 0.16%w/w | |||
ANTIFOAM | ORAL | CAPSULE, EXTENDED RELEASE | 8051089 | NA | 0.16mg | ||
ANTIFOAM | ORAL | POWDER, FOR SUSPENSION | 8051089 | NA | NA | ||
ANTIFOAM | ORAL | TABLET, COATED | 8051089 | NA | NA | ||
ANTIFOAM | ORAL | TABLET, DELAYED RELEASE | 8051089 | NA | 0.12mg | ||
ANTIPYRINE | OPHTHALMIC | SOLUTION | 60800 | T3CHA1B51H | 0.1%w/w | ||
APAFLURANE | RESPIRATORY (INHALATION) | AEROSOL, METERED | 431890 | R40P36GDK6 | 98.02%w/w | ||
APRICOT KERNEL OIL PEG-6 ESTERS | TOPICAL | CREAM | DRG3KJZ1TJ | 280mg | |||
APRICOT KERNEL OIL PEG-6 ESTERS | VAGINAL | CREAM | DRG3KJZ1TJ | 2.94%w/w | |||
AQUAPHOR | TOPICAL | CREAM | 8029150 | NA | 1%w/w | ||
AQUAPHOR | TOPICAL | OINTMENT | 8029150 | NA | 47.3%w/w | ||
AQUARIUS BP 19008 | ORAL | TABLET, EXTENDED RELEASE | NA | 33mg | |||
ARGININE | INTRAMUSCULAR | INJECTION | 74793 | 94ZLA3W45F | NA | ||
ARGININE | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | 74793 | 94ZLA3W45F | ADJ PH | ||
ARGININE | INTRAMUSCULAR | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 74793 | 94ZLA3W45F | 6240mg | ||
ARGININE | INTRAVENOUS | INJECTION | 74793 | 94ZLA3W45F | 790mg | ||
ARGININE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 74793 | 94ZLA3W45F | 3600mg | Y | |
ARGININE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 74793 | 94ZLA3W45F | 6240mg | ||
ARGININE | INTRAVENOUS | INJECTION, SOLUTION | 74793 | 94ZLA3W45F | 0.29%w/v | ||
ARGININE | INTRAVENOUS | POWDER, FOR SOLUTION | 74793 | 94ZLA3W45F | 7.07%w/v | ||
ARGININE | ORAL | TABLET | 74793 | 94ZLA3W45F | 50mg | ||
ARGININE | ORAL | TABLET, EXTENDED RELEASE | 74793 | 94ZLA3W45F | 20mg | ||
ARGININE | ORAL | TABLET, FILM COATED | 74793 | 94ZLA3W45F | 25mg | ||
ARGININE | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 74793 | 94ZLA3W45F | 20mg | ||
ARLACEL | TOPICAL | CREAM | 8029229 | NA | 3%w/w | ||
ARLACEL | TOPICAL | EMULSION | 8029229 | NA | 5.5%w/w | ||
ASCORBIC ACID | INFILTRATION | INJECTION, SOLUTION | 50817 | PQ6CK8PD0R | 0.2%w/v | ||
ASCORBIC ACID | INTRACAVITARY | INJECTION | 50817 | PQ6CK8PD0R | 5mg | ||
ASCORBIC ACID | INTRAMUSCULAR | INJECTION | 50817 | PQ6CK8PD0R | 192mg | ||
ASCORBIC ACID | INTRAVENOUS | INJECTION | 50817 | PQ6CK8PD0R | 1440mg | ||
ASCORBIC ACID | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 50817 | PQ6CK8PD0R | 2mg | ||
ASCORBIC ACID | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50817 | PQ6CK8PD0R | 1440mg | ||
ASCORBIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 50817 | PQ6CK8PD0R | 0.2%w/v | ||
ASCORBIC ACID | ORAL | CAPSULE | 50817 | PQ6CK8PD0R | 7mg | ||
ASCORBIC ACID | ORAL | CAPSULE, DELAYED RELEASE | 50817 | PQ6CK8PD0R | 2mg | ||
ASCORBIC ACID | ORAL | CAPSULE, EXTENDED RELEASE | 50817 | PQ6CK8PD0R | 17mg | ||
ASCORBIC ACID | ORAL | CONCENTRATE | 50817 | PQ6CK8PD0R | 6mg/1ml | ||
ASCORBIC ACID | ORAL | POWDER, FOR SOLUTION | 50817 | PQ6CK8PD0R | 560mg | ||
ASCORBIC ACID | ORAL | SOLUTION | 50817 | PQ6CK8PD0R | 600mg | ||
ASCORBIC ACID | ORAL | SUSPENSION | 50817 | PQ6CK8PD0R | 520mg | ||
ASCORBIC ACID | ORAL | SUSPENSION, EXTENDED RELEASE | 50817 | PQ6CK8PD0R | 5mg | ||
ASCORBIC ACID | ORAL | SYRUP | 50817 | PQ6CK8PD0R | 200mg | ||
ASCORBIC ACID | ORAL | TABLET | 50817 | PQ6CK8PD0R | 80mg | ||
ASCORBIC ACID | ORAL | TABLET, FILM COATED | 50817 | PQ6CK8PD0R | 20mg | ||
ASCORBIC ACID | ORAL | TABLET, ORALLY DISINTEGRATING | 50817 | PQ6CK8PD0R | 2.35mg | ||
ASCORBIC ACID | RECTAL | SUPPOSITORY | 50817 | PQ6CK8PD0R | 3mg | ||
ASCORBIC ACID | RESPIRATORY (INHALATION) | AEROSOL, METERED | 50817 | PQ6CK8PD0R | 0.1%w/w | ||
ASCORBIC ACID | RESPIRATORY (INHALATION) | AEROSOL, SPRAY | 50817 | PQ6CK8PD0R | 0.11%w/w | ||
ASCORBIC ACID | RESPIRATORY (INHALATION) | SOLUTION | 50817 | PQ6CK8PD0R | 0.04%w/w | ||
ASCORBIC ACID | TOPICAL | GEL | 50817 | PQ6CK8PD0R | 7mg | ||
ASCORBIC ACID | TOPICAL | SOLUTION | 50817 | PQ6CK8PD0R | 0.04%w/w | ||
ASCORBYL PALMITATE | ORAL | CAPSULE | 137666 | QN83US2B0N | 12mg | ||
ASCORBYL PALMITATE | ORAL | TABLET | 137666 | QN83US2B0N | 7.14mg | ||
ASCORBYL PALMITATE | RECTAL | SUPPOSITORY | 137666 | QN83US2B0N | 16mg | ||
ASCORBYL PALMITATE | TOPICAL | CREAM | 137666 | QN83US2B0N | 0.02%w/w | ||
ASCORBYL PALMITATE | TOPICAL | SOLUTION | 137666 | QN83US2B0N | NA | ||
ASCORBYL PALMITATE | TOPICAL | SYSTEM | 137666 | QN83US2B0N | 0.04mg | ||
ASEPTOFORM M | TOPICAL | CREAM | NA | 5%w/w | |||
ASPARTAME | BUCCAL | SYSTEM | 22839470 | Z0H242BBR1 | 1.1mg | ||
ASPARTAME | ORAL | CAPSULE, EXTENDED RELEASE | 22839470 | Z0H242BBR1 | 3mg | ||
ASPARTAME | ORAL | GRANULE, EFFERVESCENT | 22839470 | Z0H242BBR1 | 30mg | ||
ASPARTAME | ORAL | GRANULE, FOR SUSPENSION | 22839470 | Z0H242BBR1 | 420mg | ||
ASPARTAME | ORAL | LOZENGE | 22839470 | Z0H242BBR1 | 136mg | ||
ASPARTAME | ORAL | POWDER | 22839470 | Z0H242BBR1 | 450mg | ||
ASPARTAME | ORAL | POWDER, FOR SOLUTION | 22839470 | Z0H242BBR1 | 233mg | ||
ASPARTAME | ORAL | POWDER, FOR SUSPENSION | 22839470 | Z0H242BBR1 | 420mg | ||
ASPARTAME | ORAL | SOLUTION | 22839470 | Z0H242BBR1 | 40mg | ||
ASPARTAME | ORAL | SYRUP | 22839470 | Z0H242BBR1 | 0.63mg/5ml | ||
ASPARTAME | ORAL | TABLET | 22839470 | Z0H242BBR1 | 87mg | ||
ASPARTAME | ORAL | TABLET, CHEWABLE | 22839470 | Z0H242BBR1 | 195mg | ||
ASPARTAME | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 22839470 | Z0H242BBR1 | 18mg | ||
ASPARTAME | ORAL | TABLET, FILM COATED | 22839470 | Z0H242BBR1 | 20mg | ||
ASPARTAME | ORAL | TABLET, FOR SUSPENSION | 22839470 | Z0H242BBR1 | 15mg | ||
ASPARTAME | ORAL | TABLET, ORALLY DISINTEGRATING | 22839470 | Z0H242BBR1 | 180mg | ||
ASPARTAME | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 22839470 | Z0H242BBR1 | 78mg | ||
ASPARTAME | SUBLINGUAL | TABLET | 22839470 | Z0H242BBR1 | 8mg | ||
ASPARTIC ACID | INTRAVENOUS | INJECTION | 56848 | 30KYC7MIAI | 22mg |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 3, 2024
Database Last Updated: July 31, 2024